Eligibility criteria+666 characters
[...] atment plans, laboratory tests, and other study procedures.
ModuleParticipant has measurable disease per RECIST 1 (Parts A, B and C) and Module 2 (Parts A and B).1/iRECIST
Participant has cytologically or histologically confirmed l [...] and declined SoC therapy, or are intolerant of SoC therapy.
Module 1 (Parts A, B and C) and Module 2 (Parts A and B) only
Participant has measurable disease per RECIST 1.1/iRECIST.
Module 1 (Part B) and Module 2 (Part B) Only
Participant has [...] luding the lesion(s) identified for biopsy.
Module 2 (Part C and Part D)
Cohort 1 (Cervical)
Participants with histologically co [...] [...]
Secondary endpoints14 to 17 entries
Number of treatment emergent and treatment related AEs (for Module 2D only)
Incidence of Dose limiting toxicities (DLT) (for Module 2D only)
Overall Survival
Primary endpoints2 to 3 entries
Comparative efficacy (for Module 2D only)
Study descriptionrevised
[...] fects of GRWD5769 when given alone and Module 2 (Parts A to CD) which will look at the effects of GRWD5769 when given in c [...]
Study sitesdetails revised at 1 of 29 sites